An overview of gram-negative bacteria with difficult-to-treat resistance: definition, prevalence, and treatment options

References

• Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens. 2023;12(1):116. doi: 10.3390/pathogens12010116
   PubMed Web of Science ®Google Scholar
• De Oliveira DMP, Forde BM, Kidd TJ, et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020;33(3). doi: 10.1128/CMR.00181-19
   PubMed Web of Science ®Google Scholar
• Jaffal K, Bouchand F, Lawrence C, et al. Antibiotic consumption and bacterial resistance rates in hospitalized COVID-19 patients: a retrospective study during the 3 first surges. Open Forum Infect Dis. 2023;10(1):ofac680. doi: 10.1093/ofid/ofac680
   PubMed Web of Science ®Google Scholar
• Zhou N, Cheng Z, Zhang X, et al. Correction: global antimicrobial resistance: a system-wide comprehensive investigation using the global one Health index. Infect Dis Poverty. 2022;11(1):100. doi: 10.1186/s40249-022-01027-2
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH. Management of highly resistant Gram-negative infections in the Intensive Care Unit in the Era of novel antibiotics. Infect Dis Clin North Am. 2022;36(4):791–823. doi: 10.1016/j.idc.2022.08.004
   PubMed Web of Science ®Google Scholar
• CHINET, China Antimicrobial Surveillance Network. Available from: http://www.chinets.com/Data/AntibioticDrugFast.
   Google Scholar
• Leus IV, Adamiak J, Chandar B, et al. Functional diversity of Gram-negative permeability barriers reflected in antibacterial activities and intracellular accumulation of antibiotics. Antimicrob Agents Chemother. 2023;67(2):e0137722. doi: 10.1128/aac.01377-22
   PubMed Web of Science ®Google Scholar
• Hetzler L, Kollef MH, Yuenger V, et al. New antimicrobial treatment options for severe Gram-negative infections. Curr Opin Crit Care. 2022;28(5):522–533. doi: 10.1097/MCC.0000000000000968
   PubMed Web of Science ®Google Scholar
• Windham S, Kollef MH. How to use new antibiotics in the therapy of serious multidrug resistant Gram-negative infections? Curr Opin Infect Dis. 2022;35(6):561–567. doi: 10.1097/QCO.0000000000000858
   PubMed Web of Science ®Google Scholar
• Kanj SS, Bassetti M, Kiratisin P, et al. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2022;60(3):106633. doi: 10.1016/j.ijantimicag.2022.106633
   PubMed Web of Science ®Google Scholar
• Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line Agents. Clin Infect Dis. 2018;67(12):1803–1814. doi: 10.1093/cid/ciy378
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis. 2008;46(7):1121–1122. author reply 1122. doi: 10.1086/528867
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. Clin Microbiol Infect. 2012;18(3):268–281. doi: 10.1111/j.1469-0691.2011.03570.x
   PubMed Web of Science ®Google Scholar
• Zhang Z, Sun Z, Tian L. Antimicrobial resistance among pathogens causing bloodstream infections: a multicenter surveillance report over 20 years (1998-2017). Infect Drug Resist. 2022;15:249–260. doi: 10.2147/IDR.S344875
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Chen W-H, Teng L-J, et al. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents. 2005;26(1):43–49. doi: 10.1016/j.ijantimicag.2005.04.007
   PubMed Web of Science ®Google Scholar
• National Healthcare Safety Network, C.f.D.C.a.P. Antimicrobial-Resistant Phenotype Definitions. 2022 [cited 2022 Nov 14]. Available from: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/phenotype_definitions.pdf.
   Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169–e183. doi: 10.1093/cid/ciaa1478
   PubMed Web of Science ®Google Scholar
• Wolfensberger A, Kuster SP, Marchesi M, et al. The effect of varying multidrug-resistence (MDR) definitions on rates of MDR gram-negative rods. Antimicrob Resist Infect Control. 2019;8(1):193. doi: 10.1186/s13756-019-0614-3
   PubMed Web of Science ®Google Scholar
• Moglad EH, Altayb HN. Antibiogram, prevalence of methicillin-resistant and multi-drug resistant Staphylococcus spp. In different clinical samples. Saudi J Biol Sci. 2022;29(12):103432. doi: 10.1016/j.sjbs.2022.103432
   PubMed Web of Science ®Google Scholar
• Reynolds D, Burnham JP, Vazquez Guillamet C, et al. The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic. Eur Respir Rev. 2022;31(166):220068. doi: 10.1183/16000617.0068-2022
   PubMed Web of Science ®Google Scholar
• Rafailidis PI, Kofteridis D. Proposed amendments regarding the definitions of multidrug-resistant and extensively drug-resistant bacteria. Expert Rev Anti Infect Ther. 2022;20(2):139–146. doi: 10.1080/14787210.2021.1945922
   PubMed Web of Science ®Google Scholar
• Strich JR, Warner S, Lai YL, et al. Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study. Lancet Infect Dis. 2020;20(10):1172–1181. doi: 10.1016/S1473-3099(20)30153-5
   PubMed Web of Science ®Google Scholar
• Kim B, Kim J, Jo H-U, et al. Changes in the characteristics of community-onset fluoroquinolone-resistant Escherichia coli isolates causing community-acquired acute pyelonephritis in South Korea. J Microbiol Immunol Infect. 2022;55(4):678–685. doi: 10.1016/j.jmii.2022.01.001
   PubMedGoogle Scholar
• Agarwal V, Tiwari A, Varadwaj P. An extensive review on β-lactamase enzymes and their inhibitors. Curr Med Chem. 2022;30(7):783–808.
   Web of Science ®Google Scholar
• Suay-García B, Pérez-Gracia MT. Present and future of Carbapenem-Resistant Enterobacteriaceae (CRE) infections. Antibiotics. 2019;8(3):122. doi: 10.3390/antibiotics8030122
   Web of Science ®Google Scholar
• Zhang Z, Tian L. Trends in DTR, CR, ECR, and FQR in four common Gram-negative bacteria: a retrospective study from 2013 to 2021. Infect Drug Resist. 2022;15:2625–2631. doi: 10.2147/IDR.S365139
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Labate L, et al. Empirical antibiotic therapy for difficult-to-treat Gram-negative infections: when, how, and how long? Curr Opin Infect Dis. 2022;35(6):568–574. doi: 10.1097/QCO.0000000000000884
   PubMed Web of Science ®Google Scholar
• Guo Y, Han R, Jiang B, et al. In vitro activity of new β-Lactam–β-lactamase inhibitor combinations and comparators against clinical isolates of Gram-Negative Bacilli: results from the China antimicrobial surveillance Network (CHINET) in 2019. Microbiol Spectr. 2022;10(4):e0185422. doi: 10.1128/spectrum.01854-22
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Bouchillon SK, El Mahdy Kotb R, et al. In vitro activity of ceftazidime/avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from middle Eastern and African countries: ATLAS global surveillance programme 2015–18. JAC Antimicrob Resist. 2021;3(2):dlab067. doi: 10.1093/jacamr/dlab067
   PubMedGoogle Scholar
• Karlowsky JA, Lob SH, Raddatz J, et al. In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of Gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes-study for monitoring antimicrobial resistance Trends, United States 2015-2017. Clin Infect Dis. 2021;72(12):2112–2120. doi: 10.1093/cid/ciaa381
   PubMed Web of Science ®Google Scholar
• Kadri SS, Lai YL(, Ricotta EE, et al. External validation of difficult-to-treat resistance prevalence and mortality risk in Gram-negative bloodstream infection using Electronic Health Record data from 140 US hospitals. Open Forum Infect Dis. 2019;6(4):ofz110. doi: 10.1093/ofid/ofz110
   PubMed Web of Science ®Google Scholar
• Giannella M, Bussini L, Pascale R, et al. Prognostic utility of the new definition of difficult-to-treat resistance among patients with Gram-negative bloodstream infections. Open Forum Infect Dis. 2019;6(12):ofz505. doi: 10.1093/ofid/ofz505
   PubMed Web of Science ®Google Scholar
• Gajdacs M, Bátori Z, Ábrók M, et al. Characterization of resistance in Gram-negative urinary isolates using existing and novel indicators of clinical relevance: a 10-year data analysis. Life. 2020;10(2):16. doi: 10.3390/life10020016
   PubMedGoogle Scholar
• Huh K, Chung DR, Ha YE, et al. Impact of difficult-to-treat resistance in Gram-negative bacteremia on mortality: Retrospective analysis of Nationwide surveillance data. Clin Infect Dis. 2020;71(9):e487–e496. doi: 10.1093/cid/ciaa084
   PubMed Web of Science ®Google Scholar
• Rossolini GM, Bochenska M, Fumagalli L, et al. Trends of major antimicrobial resistance phenotypes in enterobacterales and gram-negative non-fermenters from ATLAS and EARS-net surveillance systems: Italian vs. European and global data, 2008-2018. Diagn Microbiol Infect Dis. 2021;101(4):115512. doi: 10.1016/j.diagmicrobio.2021.115512
   PubMed Web of Science ®Google Scholar
• Torrens G, van der Schalk TE, Cortes-Lara S, et al. Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial. J Antimicrob Chemother. 2022;77(7):1862–1872. doi: 10.1093/jac/dkac122
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Shortridge D, Harris KA, et al. Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018. Int J Infect Dis. 2021;112:321–326. doi: 10.1016/j.ijid.2021.09.064
   PubMed Web of Science ®Google Scholar
• Pascale R, Corcione S, Bussini L, et al. Non-fermentative gram-negative bloodstream infection in northern Italy: a multicenter cohort study. BMC Infect Dis. 2021;21(1):806. doi: 10.1186/s12879-021-06496-8
   PubMed Web of Science ®Google Scholar
• Kahlmeter G, Dahlager JI. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984;13(Suppl A):9–22. doi: 10.1093/jac/13.suppl_A.9
   PubMed Web of Science ®Google Scholar
• Chiu S, Hancock AM, Schofner BW, et al. Causes of polymyxin treatment failure and new derivatives to fill the gap. J Antibiot (Tokyo). 2022;75(11):593–609. doi: 10.1038/s41429-022-00561-3
   PubMed Web of Science ®Google Scholar
• Jafari F, Elyasi S. Prevention of colistin induced nephrotoxicity: a review of preclinical and clinical data. Expert Rev Clin Pharmacol. 2021;14(9):1113–1131. doi: 10.1080/17512433.2021.1933436
   PubMed Web of Science ®Google Scholar
• Nation RL, Rigatto M, Falci D, et al. Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity. Antibiotics. 2019;8(1):24. doi: 10.3390/antibiotics8010024
   Web of Science ®Google Scholar
• Karaiskos I, Gkoufa A, Polyzou E, et al. High-dose nebulized colistin methanesulfonate and the role in hospital-acquired pneumonia caused by Gram-negative bacteria with difficult-to-treat resistance: a review. Microorganisms. 2023;11(6):1459. doi: 10.3390/microorganisms11061459
   PubMed Web of Science ®Google Scholar
• Bassetti M, Labate L, Russo C, et al. Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective. Expert Opin Pharmacother. 2021;22(2):167–177. doi: 10.1080/14656566.2020.1817386
   PubMed Web of Science ®Google Scholar
• Kaewpoowat Q, Ostrosky-Zeichner L. Tigecycline: a critical safety review. Expert Opin Drug Saf. 2015;14(2):335–342. doi: 10.1517/14740338.2015.997206
   PubMed Web of Science ®Google Scholar
• Wu X, Zhu Y, Chen Q, et al. Tigecycline therapy for nosocomial pneumonia due to carbapenem-resistant Gram-negative bacteria in critically Ill patients who received inappropriate initial antibiotic treatment: a retrospective case study. Biomed Res Int. 2016;2016:1–7. doi: 10.1155/2016/8395268
   Web of Science ®Google Scholar
• Abdallah TAK, Elajez R, Ibrahim TB, et al. Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections. J Infect Public Health. 2021;14(11):1620–1622. doi: 10.1016/j.jiph.2021.09.025
   PubMed Web of Science ®Google Scholar
• Yahav D, Giske CG, Grāmatniece A, et al. New β-Lactam–β-lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34(1). doi: 10.1128/CMR.00115-20
   PubMed Web of Science ®Google Scholar
• Bassetti M, Peghin M, Vena A, et al. Treatment of infections due to MDR Gram-negative bacteria. Front Med. 2019;6:74. doi: 10.3389/fmed.2019.00074
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Karaiskos I. Current and potential therapeutic options for infections caused by difficult-to-treat and pandrug resistant Gram-negative bacteria in critically Ill patients. Antibiotics. 2022;11(8):1009. doi: 10.3390/antibiotics11081009
   Google Scholar
• Larcher R, Laffont-Lozes P, Roger C, et al. Last resort beta-lactam antibiotics for treatment of New-Delhi metallo-beta-lactamase producing Enterobacterales and other difficult-to-treat resistance in Gram-negative bacteria: a real-life study. Front Cell Infect Microbiol. 2022;12:1048633. doi: 10.3389/fcimb.2022.1048633
   PubMed Web of Science ®Google Scholar
• Rodriguez-Aguirregabiria M, Asensio-Martin MJ, Nanwani-Nanwani KL. Recurrent ventilator-associated pneumonia caused by “difficult to treat” resistance Pseudomonas aeruginosa. Rev Esp Quimioter. 2022;35(Suppl 1):117–119. doi: 10.37201/req/s01.25.2022
   PubMedGoogle Scholar
• Burastero GJ, Orlando G, Santoro A, et al. Ceftazidime/Avibactam in ventilator-associated pneumonia due to difficult-to-treat non-fermenter Gram-negative bacteria in COVID-19 patients: a case series and review of the literature. Antibiotics. 2022;11(8):1007. doi: 10.3390/antibiotics11081007
   Google Scholar
• Contreras-Gomez MJ, Martinez JRW, Rivas L, et al. Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa. Front Pharmacol. 2022;13:1007162. doi: 10.3389/fphar.2022.1007162
   PubMed Web of Science ®Google Scholar
• Soriano MC, Montufar J, Blandino-Ortiz A. Cefiderocol Rev Esp Quimioter. 2022;35(Suppl 1):31–34. doi: 10.37201/req/s01.07.2022
   PubMedGoogle Scholar
• Fendian ÁM, Albanell-Fernández M, Tuset M, et al. Real-life data on the effectiveness and safety of Cefiderocol in severely infected patients: a case series. Infect Dis Ther. 2023;12(4):1205–1216. doi: 10.1007/s40121-023-00776-3
   PubMedGoogle Scholar
• Marcelo C, de Gea Grela A, Palazuelos MM, et al. Clinical cure of a difficult-to-treat resistant Pseudomonas aeruginosa ventriculitis using Cefiderocol: a case report and literature review. Open Forum Infect Dis. 2022;9(8):ofac391. doi: 10.1093/ofid/ofac391
   PubMed Web of Science ®Google Scholar
• Scott CJ, Zhu E, Jayakumar RA, et al. Efficacy of eravacycline versus best Previously Available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR) Acinetobacter baumannii. Ann Pharmacother. 2022;56(12):1299–1307. doi: 10.1177/10600280221085551
   PubMed Web of Science ®Google Scholar
• Gatti M, Pea F. Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams. Expert Rev Anti Infect Ther. 2023;21(2):149–166. doi: 10.1080/14787210.2023.2169131
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Sepulcri C, et al. Treatment of bloodstream infections due to Gram-negative bacteria with difficult-to-treat resistance. Antibiotics. 2020;9(9):632. doi: 10.3390/antibiotics9090632
   Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 Guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75(2):187–212. doi: 10.1093/cid/ciac268
   PubMed Web of Science ®Google Scholar
• [Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults(2022)]. Zhonghua Jie He He Hu Xi Za Zhi. 2022;45(8):739–752. doi: 10.3760/cma.j.cn112147-20220407-00290
   PubMedGoogle Scholar
• Naylor NR, Atun R, Zhu N, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control. Antimicrob Resist Infect Control. 2018;7(1):58. doi: 10.1186/s13756-018-0336-y
   PubMedGoogle Scholar
• Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66. doi: 10.1016/S1473-3099(18)30605-4
   PubMed Web of Science ®Google Scholar
• Murray CJL, Ikuta KS, Sharara F. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. doi: 10.1016/S0140-6736(21)02724-0
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Endimiani A, Taracila MA, et al. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943–4960. doi: 10.1128/AAC.00296-11
   PubMed Web of Science ®Google Scholar
• Lee YL, Chen H-M, Hii I-M, et al. Carbapenemase-producing Enterobacterales infections: recent advances in diagnosis and treatment. Int J Antimicrob Agents. 2022;59(2):106528. doi: 10.1016/j.ijantimicag.2022.106528
   PubMed Web of Science ®Google Scholar
• P N, Kumar D, Meena DS, et al. Difficult-to-treat resistant gram-negative blood stream infections – the beginning of a superbug era – a prospective observational study. Indian J Med Microbiol. 2023;44:100364. doi: 10.1016/j.ijmmb.2023.02.007
   PubMed Web of Science ®Google Scholar
• Daneman N, Fridman D, Johnstone J, et al. Antimicrobial resistance and mortality following E. coli bacteremia. EClinicalMedicine. 2023;56:101781. doi: 10.1016/j.eclinm.2022.101781
   PubMedGoogle Scholar
• Bonine NG, Berger A, Altincatal A, et al. Impact of delayed appropriate antibiotic therapy on patient outcomes by antibiotic resistance status from serious Gram-negative bacterial infections. Am J Med Sci. 2019;357(2):103–110. doi: 10.1016/j.amjms.2018.11.009
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF, Micek ST, et al. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014;18(6):596. doi: 10.1186/s13054-014-0596-8
   PubMed Web of Science ®Google Scholar
• Baltas I, Stockdale T, Tausan M, et al. Impact of antibiotic timing on mortality from Gram-negative bacteraemia in an English district general hospital: the importance of getting it right every time. J Antimicrob Chemother. 2021;76(3):813–819. doi: 10.1093/jac/dkaa478
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Lagou S, Pontikis K, et al. The “old” and the “new” antibiotics for MDR Gram-negative pathogens: for whom, when, and how. Front Public Health. 2019;7:151. doi: 10.3389/fpubh.2019.00151
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Saffioti C, Losito AR, et al. Use of colistin in adult patients: a cross-sectional study. J Glob Antimicrob Resist. 2020;20:43–49. doi: 10.1016/j.jgar.2019.06.009
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400. doi: 10.1016/S1473-3099(18)30099-9
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Mack AR, Taracila MA, et al. Resistance to novel β-Lactam–β-lactamase inhibitor combinations. Infectious Disease Clinics Of North America. 2020;34(4):773–819. doi: 10.1016/j.idc.2020.05.001
   PubMed Web of Science ®Google Scholar
• Gajdács M, Albericio F. Antibiotic resistance: from the bench to patients. Antibiotics. 2019;8(3):129. doi: 10.3390/antibiotics8030129
   Web of Science ®Google Scholar
• Zak-Doron Y, Dishon Benattar Y, Pfeffer I, et al. The Association between empirical antibiotic treatment and mortality in severe infections caused by carbapenem-resistant Gram-negative bacteria: a prospective study. Clin Infect Dis. 2018;67(12):1815–1823. doi: 10.1093/cid/ciy371
   PubMed Web of Science ®Google Scholar
• Burnham JP, Lane MA, Kollef MH. Impact of sepsis classification and multidrug-resistance status on outcome among patients treated with appropriate therapy. Crit Care Med. 2015;43(8):1580–1586. doi: 10.1097/CCM.0000000000001013
   PubMed Web of Science ®Google Scholar
• Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the fight against multidrug-resistant bacteria 2005–2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. Clin Infect Dis. 2017;65(1):141–146. doi: 10.1093/cid/cix246
   PubMed Web of Science ®Google Scholar
• Bassetti M, Kanj SS, Kiratisin P, et al. Early appropriate diagnostics and treatment of MDR Gram-negative infections. JAC Antimicrob Resist. 2022;4(5):dlac089. doi: 10.1093/jacamr/dlac089
   PubMedGoogle Scholar
• Teitelbaum D, Elligsen M, Katz K, et al. Introducing the escalation Antibiogram: a simple tool to inform changes in empiric antimicrobials in the nonresponding patient. Clin Infect Dis. 2022;75(10):1763–1771. doi: 10.1093/cid/ciac256
   PubMed Web of Science ®Google Scholar
• Guarascio AJ, Brickett LM, Porter TJ, et al. Development of a statewide Antibiogram to assess regional Trends in antibiotic-resistant ESKAPE organisms. J Pharm Pract. 2019;32(1):19–27. doi: 10.1177/0897190017735425
   PubMed Web of Science ®Google Scholar
• Echols RM, Tillotson GS. Difficult to treat: do we need a new definition? Clin Infect Dis. 2019;69(9):1641–1642. doi: 10.1093/cid/ciz184
   PubMed Web of Science ®Google Scholar
• Kadri SS, Danner RL. Reply to Raoult and Rolain, and to Echols and Tillotson. Clin Infect Dis. 2019;69(9):1642–1644. doi: 10.1093/cid/ciz186
   PubMedGoogle Scholar